ImmuPharma (LON:IMM) Shares Up 25.3% - Should You Buy?

Key Points

• ImmuPharma's shares rose by 25.3% on Monday, reaching a trading high of GBX 19.35 ($0.26) before closing at GBX 17.51 ($0.24) with a trading volume increase of 677% compared to the average.
• The company reported a net margin of 3,519.56% with earnings per share of GBX (0.38) in its last quarterly results, indicating significant volatility in financial performance.
• ImmuPharma specializes in peptide-based therapeutics aimed at treating autoimmune diseases, with its lead product, Lupuzor™, showing promise for various conditions related to autophagy mechanisms.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 25.3% during mid-day trading on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). 65,638,188 shares traded hands during trading, an increase of 677% from the average session volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Trading Up 25.3%

The company has a market cap of £87.51 million, a P/E ratio of -1,967.53 and a beta of 1.53. The stock's 50-day moving average price is GBX 3.43 and its 200-day moving average price is GBX 3.01.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.